AGY Stoklara Genel Bakış Ticari bir biyoteknoloji şirketi olan Allergy Therapeutics plc, alerjik rahatsızlıkların teşhis ve tedavisine odaklanmaktadır. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
Allergy Therapeutics plc Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti Allergy Therapeutics Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı UK£0.064 52 Haftanın En Yüksek Seviyesi UK£0.065 52 Haftanın En Düşük Seviyesi UK£0.018 Beta 1.38 1 Aylık Değişim 25.49% 3 Aylık Değişim 41.44% 1 Yıllık Değişim 190.91% 3 Yıllık Değişim -80.61% 5 Yıllık Değişim -36.63% Halka arzdan bu yana değişim -91.41%
Son Haberler & Güncellemeler Daha fazla güncelleme görün
Less than half of directors are independent Nov 28
Allergy Therapeutics plc Submits Marketing Authorisation Application for Grass MATA MPL Nov 26
Allergy Therapeutics plc, Annual General Meeting, Dec 16, 2024 Nov 22
Allergy Therapeutics plc (LON:AGY) Soars 27% But It's A Story Of Risk Vs Reward Nov 09
Full year 2024 earnings: EPS exceeds analyst expectations Nov 07
New minor risk - Financial data availability Oct 13
Not Many Are Piling Into Allergy Therapeutics plc (LON:AGY) Just Yet Sep 12
New major risk - Share price stability Aug 14
Allergy Therapeutics plc Provides Revenue Guidance for the Second Half and Year Ended 30 June 2024 Jul 23
Allergy Therapeutics plc Appoints David Ball as Non- Executive Director and Chair of the Board's Audit and Risk Committee Jun 27
Allergy Therapeutics plc's (LON:AGY) 28% Share Price Surge Not Quite Adding Up May 21
Allergy Therapeutics plc Provides Further Details from Positive Top Line Results from G306 Phase III Field Study G306 to Evaluate the Efficacy and Safety of Grass MATA MPL May 08
Less than half of directors are independent Apr 10
Allergy Therapeutics Announces Resignation of Mary Tavener as Non-Executive Director Apr 03
Allergy Therapeutics plc Provides Sales Guidance for the Second Half and Full Year Ending on 30 June 2024 Mar 29
First half 2024 earnings released: UK£0.006 loss per share (vs UK£0.013 loss in 1H 2023) Mar 29
New minor risk - Financial data availability Mar 17
Allergy Therapeutics plc Announces Appointment of Shaun Furlong to Board of Directors Mar 12
Allergy Therapeutics plc, Annual General Meeting, Mar 08, 2024 Feb 10
Allergy Therapeutics plc (LON:AGY) Surges 28% Yet Its Low P/S Is No Reason For Excitement Dec 18
Allergy Therapeutics plc Provides an Update on the Data Analysis of Its Pivotal G306 Phase III Trial of Grass MATA MPL Dec 13
Allergy Therapeutics plc Announces Interim Top Line Results from its Pivotal G306 Phase III Trial of Grass MATA MPL Nov 14
New major risk - Revenue and earnings growth Oct 31 Allergy Therapeutics plc has completed a Follow-on Equity Offering in the amount of £6.891025 million. Oct 14
New major risk - Shareholder dilution Oct 13
Full year 2023 earnings: EPS and revenues miss analyst expectations Sep 28
Allergy Therapeutics plc Announces the Completion of Dosing of Healthy Volunteers in the First Two Cohorts in the Phase I Protect Trial of Its Novel Virus-Like Particle (Vlp)-Based Peanut Allergy Vaccine Candidate Sep 26
Allergy Therapeutics plc Announces Executive Changes Jul 11
First half 2023 earnings: EPS misses analyst expectations Jun 20
Allergy Therapeutics plc Provides Sales Guidance for the Second Half Year to 30 June 2023 and Full Year to 30 June 2024 Jun 20
Less than half of directors are independent Jun 19
Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended 31 December 2022 Jan 20
Allergy Therapeutics plc, Annual General Meeting, Feb 07, 2023 Jan 14
Allergy Therapeutics Announces Resignation of Scott Leinenweber as Non-Executive Director Dec 28
Allergy Therapeutics Announces Key Updates on Grass MATA MPL and VLP Peanut Clinical Programmes Dec 09
Allergy Therapeutics plc Announces Board Appointments Dec 07
Allergy Therapeutics plc Appoints Martin Hopcroft as Interim CFO Nov 21 Allergy Therapeutics plc Resumes UK Manufacturing Production Allergy Therapeutics plc announced that it has received £17 million in funding from Southern Fox Investments Limited Oct 19
Consensus forecasts updated Oct 06 Allergy Therapeutics plc announced that it expects to receive £10 million in funding from Southern Fox Investments Ltd. and other investor Oct 01
Full year 2022 earnings: EPS and revenues miss analyst expectations Sep 30
Allergy Therapeutics plc, Annual General Meeting, Oct 17, 2022 Sep 30
Price target increased to UK£0.67 Jul 27 Allergy Therapeutics plc Provides Revenue Guidance for the Year Ended 30 June 2022 Allergy Therapeutics plc Announces Resignation of Nick Wykeman to Its Board Director, Effective from November 30, 2022
Price target increased to UK£0.59 Apr 27
Less than half of directors are independent Apr 27
Allergy Therapeutics Shares Data at WAO-BSACI Apr 26
First half 2022 earnings: EPS exceeds analyst expectations Mar 05
Allergy Therapeutics plc Announces the Presentation of Positive New Data from Its Two Lead Immunotherapy Programmes At the 2022 American Academy of Allergy Asthma and Immunology Annual Meeting Held in Phoenix, Arizona Mar 03
FDA Clears Allergy Therapeutics Investigational New Drug Application for Its Novel Virus-Like Particle (VLP )-Based Peanut Allergy Vaccine Candidate Jan 26
Allergy Therapeutics plc Provides Revenue Guidance for the Six Months Ended December 31, 2021 Jan 13
Senior Independent Director Stephen Smith has left the company Nov 29
Senior Independent Director Stephen Smith has left the company Nov 29
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 28
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 27
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26
Senior Independent Director Stephen Smith has left the company Nov 26 Hissedar Getirileri AGY GB Pharmaceuticals GB Pazar 7D 3.2% -1.7% -2.6% 1Y 190.9% -3.5% 2.4%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: AGY geçen yıl % -3.5 oranında getiri sağlayan UK Pharmaceuticals sektörünü aştı.
Getiri vs Piyasa: AGY geçen yıl % 2.4 oranında getiri sağlayan UK Piyasasını aştı.
Fiyat Oynaklığı Is AGY's price volatile compared to industry and market? AGY volatility AGY Average Weekly Movement 8.7% Pharmaceuticals Industry Average Movement 6.1% Market Average Movement 4.8% 10% most volatile stocks in GB Market 10.6% 10% least volatile stocks in GB Market 2.6%
İstikrarlı Hisse Senedi Fiyatı: AGY hisse senedi fiyatı son 3 aydır dalgalı bir seyir izliyor.
Zaman İçindeki Volatilite: AGY 'nin haftalık oynaklığı ( 9% ) geçen yıl boyunca sabit kaldı, ancak hala UK hisselerinin %75'inden yüksek.
Şirket Hakkında Ticari bir biyoteknoloji şirketi olan Allergy Therapeutics plc, alerjik rahatsızlıkların teşhis ve tedavisine odaklanmaktadır. Şirket, enjekte edilebilir ve dilaltı alerjen spesifik immünoterapiler satmakta; özellikle otlara, yabani otlara ve ağaçlara karşı polenle ilişkili alerjilerin tedavisinin yanı sıra teşhis ürünleri de sunmaktadır. Ürünleri arasında Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics ve Acarovac Plus bulunmaktadır.
Daha fazla göster Allergy Therapeutics plc Temel Bilgiler Özeti Allergy Therapeutics'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? AGY temel i̇stati̇sti̇kler Piyasa değeri UK£305.68m Kazançlar(TTM ) -UK£40.22m Gelir(TTM ) UK£55.20m
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) AGY gelir tablosu (TTM ) Gelir UK£55.20m Gelir Maliyeti UK£25.46m Brüt Kâr UK£29.74m Diğer Giderler UK£69.95m Kazançlar -UK£40.22m
Son Raporlanan Kazançlar
Jun 30, 2024
Hisse başına kazanç (EPS) -0.0084 Brüt Marj 53.87% Net Kâr Marjı -72.86% Borç/Özkaynak Oranı 622.8%
AGY uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görün
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/22 01:42 Gün Sonu Hisse Fiyatı 2024/12/20 00:00 Kazançlar 2024/06/30 Yıllık Kazançlar 2024/06/30
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları Allergy Therapeutics plc 8 Bu analistlerden 1, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Adam McCarter Cavendish Patrick Trucchio H.C. Wainwright & Co. Gary Waanders Nomura Code Securities Limited
Göster 5 daha fazla analist 
